Contract Notice Detail
Summary Information
Summary Information
Base Total Price:
16,265.6000 Euro
Request Reference:
10C0571924
Request Name:
Aquisição de NIVOLUMAB IV 10 MG/ML 4 ML SOL INJ ao abrigo do CPA 2023_491 para a ULSASI para o ano 2024
Phase:
Tendering Phase
State:
Awarded
Description:
Aquisição de NIVOLUMAB IV 10 MG/ML 4 ML SOL INJ ao abrigo do CPA 2023_491 para a ULSASI para o ano 2024
Procedure Type:
VortalGOV - Acquisition under a Framework Agreement (via Direct Award)
Lot Name
Lot Base Price
Expected Duration
N160 - NIVOLUMAB [10 MG/ML; 4 ML; SOL INJ; FRS]
-
6
(
Months
)
Object of the Contract
Object of the Contract
Type of Contract:
Supplies Acquisition
Main Object CPV Main Category:
Ic19 Amadora 2700 Venteira Amadora Lisboa PORTUGAL
CPV Main Vocabulary
33600000-6 - Pharmaceutical products
CPV Supplementary Vocabulary
Additional Classifications List
Scheduling
Scheduling
Request online publishing date:
6/24/2024 9:50 AM
(UTC +1 hour)
National official publishing date and time (DR):
9/4/2023 12:00 AM
(UTC +1 hour)
Due datetime for receiving replies:
6/27/2024 5:00 PM
(UTC +1 hour)
Financial Settings
Financial Settings
Define Warranties?
No
Contract Documents
Contract Documents
Document Name
Description
Doc Classification
Anexo I - Solictação de cotação.xlsx
Anexo I - Solictação de cotação.xlsx
Download
Convite 10C0571924.pdf
Convite 10C0571924.pdf
Download
Object of contract
This contract is subject to renewal?
No
The procurement is related to a project and/or programme financed by European Union funds?
No
Legal, economic, financial and technical information
The contract is reserved to sheltered workshops and economic operators aiming at the social and professional integration of disabled or disadvantaged persons?
No
Questionnaire
Questionnaire
1
Lot Title
N160 - NIVOLUMAB [10 MG/ML; 4 ML; SOL INJ; FRS]
Base Price
16 265,6000
1.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
N160
NIVOLUMAB [10 MG/ML; 4 ML; SOL INJ; FRS]
40,0000
UN
Buyer Comment:
500048193 | Bristol - Myers Squibb Farmacêutica Portuguesa, S.A. | CPA:2023491/115/0146 | NºAIM:5655865;
TOTAL
(The amounts shown do not include VAT)
Evaluation
Evaluation
Vision
Avaliação
Definir modelo de avaliação
Sim
Não
Modalidade de avaliação
Selecione…
Monofator
Método de Avaliação
Selecione…
Manual
Divulgar critérios de avaliação
Sim
Não
Critérios da Avaliação
1 - N160 - NIVOLUMAB [10 MG/ML; 4 ML; SOL INJ; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
-
100%
Normas de desempate
Public Messages
Public Messages
Type
Reference
Subject
Date
No items found...